Lupin Limited announced a significant regulatory milestone, receiving tentative approval from the United States Food and Drug Administration for its Sugammadex Injection. The approval covers two dosage strengths and represents an important addition to the company's pharmaceutical portfolio in the U.S. market.

FDA Approval Details

The U.S. FDA has granted tentative approval for Lupin's Abbreviated New Drug Application for Sugammadex Injection in the following specifications:

Therapeutic Application

Sugammadex Injection is specifically indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in surgical patients. The product serves a critical role in anesthesia management, allowing healthcare professionals to reverse muscle relaxation effects in both adult and pediatric patients aged 2 years and older during surgical procedures.

Company Profile

Lupin Limited operates as a global pharmaceutical leader headquartered in Mumbai, India, with products distributed across over 100 markets worldwide. The company maintains a diversified portfolio spanning branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The company's therapeutic focus areas include:

• Respiratory treatments
• Cardiovascular medications
• Anti-diabetic products
• Anti-infective drugs
• Gastrointestinal treatments
• Central nervous system therapies
• Women's health products

Global Operations

Lupin's manufacturing and research infrastructure comprises 15 state-of-the-art manufacturing sites and 7 research centers globally. The company employs over 22,000 professionals worldwide and has established subsidiaries including Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions to expand its healthcare ecosystem.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was communicated to both the National Stock Exchange of India Limited and BSE Limited, signed by Company Secretary & Compliance Officer Amit Kumar Gupta.

Lupin 's subsidiary Multicare Pharmaceuticals Philippines (MPPI) has executed a substantial share buyback program, repurchasing 2,813,811 shares from existing shareholders. The transaction was disclosed through a regulatory filing under Regulation 30 of the SEBI Listing Regulations, with the buyback completed using MPPI's retained earnings.

Share Buyback Transaction Details

The buyback has resulted in a significant ownership restructuring within the Philippines-based pharmaceutical subsidiary. Nanomi B.V., Netherlands, which is a wholly owned subsidiary of Lupin, did not participate in the buyback process, leading to an automatic increase in its proportional shareholding.

MPPI Financial Performance

Multicare Pharmaceuticals Philippines, incorporated in November 2001, operates in trading, importing, marketing, and distributing pharmaceutical products and medical devices. The company has demonstrated consistent operational performance with varying revenue trends over recent years.

Regulatory Compliance

The transaction has been properly disclosed pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations. The buyback does not fall within the purview of related party transactions, and no promoter or group companies have any interest in the transaction. The ownership change became effective immediately upon completion of the buyback process.

Strategic Impact

This corporate action strengthens Lupin's control over its Philippines operations through increased subsidiary ownership. The buyback represents efficient capital allocation within MPPI while enhancing Nanomi's strategic position in the Philippine pharmaceutical market without requiring additional investment from the parent entity.